EWTX

MKT CAP:$3B

Edgewise Therapeutics, Inc.

Market Cap

$3B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$31.23+$7.48 (+31.49%)

Apr 23, 2026

Company Details

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root ...

CEO

Kevin Koch

IPO Date

Mar 26, 2021

Website

www.edgewisetx.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$157M

EPS (Diluted)

-$1.58

Free Cash Flow

-$133M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q4 2025

May 14, 2026

PENDING

FY 2025

Feb 26, 2026

$0EPS -$1.63

Q3 2025

Nov 6, 2025

$0EPS -$0.39

Q2 2025

Aug 7, 2025

$0EPS -$0.34

Q1 2025

May 8, 2025

$0EPS -$0.43

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 21	$0	$0	-$13M
Q1 22	$0	$0	-$15M
Q2 22	$0	$0	-$16M
Q3 22	$0	$0	-$18M
Q4 22	$0	$0	-$22M
Q1 23	$0	$0	-$26M
Q2 23	$0	$0	-$25M
Q3 23	$0	$0	-$29M
Q4 23	$0	$0	-$34M
Q1 24	$0	$0	-$35M
Q2 24	$0	$0	-$38M
Q3 24	$0	$0	-$40M
Q4 24	$0	$0	-$46M
Q1 25	$0	$0	-$46M
Q2 25	$0	$0	-$43M
Q3 25	$0	$0	-$47M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	-$9M	-$9M
Q1 22	-$13M	-$13M
Q2 22	-$16M	-$17M
Q3 22	-$12M	-$13M
Q4 22	-$12M	-$15M
Q1 23	-$23M	-$27M
Q2 23	-$20M	-$21M
Q3 23	-$22M	-$23M
Q4 23	-$27M	-$27M
Q1 24	-$29M	-$29M
Q2 24	-$26M	-$26M
Q3 24	-$27M	-$28M
Q4 24	-$27M	-$27M
Q1 25	-$38M	-$38M
Q2 25	-$33M	-$33M
Q3 25	-$35M	-$35M

Capital Expenditures

Quarter	CapEx
Q4 21	$79.0K
Q1 22	$369.0K
Q2 22	$554.0K
Q3 22	$1M
Q4 22	$3M
Q1 23	$4M
Q2 23	$759.0K
Q3 23	$457.0K
Q4 23	$161.0K
Q1 24	$297.0K
Q2 24	$221.0K
Q3 24	$520.0K
Q4 24	$274.0K
Q1 25	$44.0K
Q2 25	$50.0K
Q3 25	$89.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 21	—	+102.1%
Q1 22	—	+116.2%
Q2 22	—	+57.7%
Q3 22	—	+39.7%
Q4 22	—	+72.2%
Q1 23	—	+73.4%
Q2 23	—	+53.7%
Q3 23	—	+61.3%
Q4 23	—	+53.4%
Q1 24	—	+35.2%
Q2 24	—	+50.4%
Q3 24	—	+37.3%
Q4 24	—	+34.5%
Q1 25	—	+32.2%
Q2 25	—	+11.8%
Q3 25	—	+15.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$2M	—
Q1 22	$2M	—
Q2 22	$2M	—
Q3 22	$3M	—
Q4 22	$4M	—
Q1 23	$4M	—
Q2 23	$0	—
Q3 23	$5M	—
Q4 23	$5M	—
Q1 24	$5M	—
Q2 24	$5M	—
Q3 24	$7M	—
Q4 24	$8M	—
Q1 25	$9M	—
Q2 25	$8M	—
Q3 25	$8M	—

OpEx Breakdown

Quarter	R&D	G&A
Q4 21	$9M	$4M
Q1 22	$11M	$4M
Q2 22	$12M	$4M
Q3 22	$14M	$4M
Q4 22	$17M	$5M
Q1 23	$20M	$6M
Q2 23	$20M	$6M
Q3 23	$24M	$6M
Q4 23	$28M	$6M
Q1 24	$28M	$7M
Q2 24	$31M	$7M
Q3 24	$32M	$8M
Q4 24	$36M	$9M
Q1 25	$37M	$9M
Q2 25	$34M	$9M
Q3 25	$37M	$9M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$34M	$231M	$266M
Q2 22	$18M	$230M	$248M
Q3 22	$110M	$255M	$365M
Q4 22	$22M	$330M	$352M
Q1 23	$48M	$280M	$328M
Q2 23	$32M	$278M	$310M
Q3 23	$33M	$257M	$290M
Q4 23	$86M	$232M	$318M
Q1 24	$30M	$502M	$533M
Q2 24	$43M	$468M	$512M
Q3 24	$45M	$448M	$493M
Q4 24	$42M	$429M	$470M
Q1 25	$50M	$386M	$436M
Q2 25	$43M	$551M	$594M
Q3 25	$46M	$517M	$563M
Q4 25	$61M	$469M	$530M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 21	49M	0.0%	+142.2%
Q1 22	50M	+0.6%	+0.6%
Q2 22	50M	+0.2%	+0.7%
Q3 22	52M	+4.5%	+5.2%
Q4 22	63M	+22.0%	+28.4%
Q1 23	63M	+0.1%	+27.7%
Q2 23	63M	+0.2%	+27.7%
Q3 23	63M	+0.1%	+22.4%
Q4 23	65M	+2.1%	+2.4%
Q1 24	88M	+35.2%	+38.4%
Q2 24	94M	+6.8%	+47.5%
Q3 24	94M	+0.3%	+47.8%
Q4 24	92M	-1.5%	+42.7%
Q1 25	95M	+2.9%	+8.6%
Q2 25	105M	+10.3%	+12.2%
Q3 25	105M	+0.5%	+12.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 21	$0	31
Q1 22	$0	31
Q2 22	$0	31
Q3 22	$0	31
Q4 22	$0	59
Q1 23	$0	59
Q2 23	$0	59
Q3 23	$0	59
Q4 23	$0	88
Q1 24	$0	88
Q2 24	$0	88
Q3 24	$0	88
Q4 24	$0	110
Q1 25	$0	110
Q2 25	$0	110
Q3 25	$0	110

Revenue / Employee